Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.

R. Eskander,K. Tewari
DOI: https://doi.org/10.1016/j.ygyno.2013.11.029
IF: 5.304
2014-02-01
Gynecologic Oncology
Abstract:
What problem does this paper attempt to address?